Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies. BioImage complements Fisher Biosciences' existing Cellomics business. BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution(R) technology. Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.
"The addition of BioImage further enhances our portfolio of high content cell-based assays and reagents," said Ron Lowy, president and chief executive officer of Fisher Biosciences. "Adding BioImage's Redistribution IP, assays, cell-lines and services to our already strong offering of high content screening instrumentation, software, siRNA and assay reagent kits, provides a more complete range of options to customers and strengthens Fisher's leadership position in high content screening."